Bicara Therapeutics (BCAX) Change in Accured Expenses (2023 - 2026)

Bicara Therapeutics' Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $11.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 257.58% year-over-year to $11.7 million in Q1 2026; TTM through Mar 2026 was $11.2 million, a 18.51% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, down 57.7% from the prior year.
• Change in Accured Expenses grew to $11.7 million in Q1 2026 per BCAX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $11.7 million in Q1 2026 and bottomed at -$1.8 million in Q2 2025.
• The 4-year median for Change in Accured Expenses is $991500.0 (2024), against an average of $2.5 million.
• Biggest YoY gain for Change in Accured Expenses was 692.03% in 2025; the steepest drop was 82.57% in 2025.
• Year by year, Change in Accured Expenses stood at $4.2 million in 2023, then surged by 114.21% to $9.0 million in 2024, then slumped by 82.57% to $1.6 million in 2025, then soared by 647.29% to $11.7 million in 2026.
• Per Business Quant, the three latest BCAX Change in Accured Expenses figures stand at $11.7 million (Q1 2026), $1.6 million (Q4 2025), and -$265000.0 (Q3 2025).